Addex reports anti-tussive activity of GABAB positive allosteric modulator

Addex Therapeutics (ADXN) announced robust anti-tussive activity of its novel gamma-aminobutyric acid sub-type B receptor positive allosteric modulator in multiple preclinical models of chronic cough compared to reference drugs. Some of these preclinical data with Addex GABAB PAM drug candidate will be presented on June 7 at the 10th American Cough Conference, in Dulles, Virginia by Mikhail Kalinichev, head of translational science at Addex. In models of chronic cough, the GABAB PAM drug candidate significantly reduced citric acid-induced cough frequency, increased cough latency and showed no signs of tolerance after sub-chronic treatment. In the same model, the antitussive efficacy of the Addex GABAB PAM drug candidate appears to be superior to that observed with nalbuphine, baclofen, codeine or a P2X3 inhibitor. In addition, the tolerability of the GABAB PAM candidate demonstrated better tolerability and a wider therapeutic margin than that observed with nalbuphine, baclofen, or codeine, while being similar to that of a P2X3 inhibitor, based on the compound’s activity on respiratory rate.